Biocon Overhauls Top Management as It Integrates Biocon Biologics

Biocon Limited ( (IN:BIOCON) ) just unveiled an announcement.

Biocon’s board has approved a significant reshaping of its leadership as part of its ongoing integration with Biocon Biologics, accepting the resignation of CEO and Managing Director Siddharth Mittal and interim CFO Mukesh Kamath, both of whom will move to other roles within the group. Shreehas Pradeep Tambe, currently CEO and MD of Biocon Biologics, will become CEO and MD of Biocon from April 1, 2026, while Biocon Biologics’ CFO Kedar Narayan Upadhye will assume the CFO role at Biocon, underscoring a deeper operational alignment between the entities.

The company is further consolidating key functions by appointing Biocon Biologics executives to critical governance and senior management roles, including Akhilesh Nand as Head of Governance, Risk and Compliance and Naveen Narayanan and Mandar Shrikant Ghatnekar as Chief Human Resources Officer and Chief Technology Officer, respectively. At the same time, several existing senior managers, including heads of commercial, scientific, operations, HR, quality, supply chain and API commercials, will cease to be senior management personnel after March 31, 2026, signaling a broad organizational restructuring to support the unified biopharmaceutical strategy.

More about Biocon Limited

Biocon Limited is an India-based biopharmaceutical company headquartered in Bengaluru, focusing on biologics, biosimilars and other pharmaceutical products for global markets. Through its subsidiary Biocon Biologics Limited, the group aims to build a unified global biopharmaceutical platform, strengthening its presence in regulated and emerging markets.

Average Trading Volume: 171,147

Technical Sentiment Signal: Buy

Current Market Cap: 614.9B INR

Learn more about BIOCON stock on TipRanks’ Stock Analysis page.